Reporting after the markets closed Tuesday, the industry's second largest biotech company by market cap, Amgen Inc., not only provided exceptionally strong second quarter financial results but also revealed its plans for significant corporate changes. The Thousand Oaks, Calif.-based company said it will shed approximately 12 percent to 15 percent of its global work force.